Wanbury ropes in Prakash Venkatraman as President of API business

Published On 2024-08-16 10:23 GMT   |   Update On 2024-08-16 10:23 GMT
Advertisement

Mumbai: Wanbury Limited has announced the appointment of Prakash Venkatraman as President of the API business. With a stellar career spanning over three decades, Venkatraman has a wealth of experience in API operations, P&L management, and business strategy.

Venkatraman most recently served as Senior Vice President of the API business at Shilpa Pharma Lifesciences for over 3 years. In this role, he spearheaded the API division, driving growth and delivering on revenue and EBITDA targets.

Advertisement

Previously, Venkatraman led Global Sales and Business Development for Sun Pharma's API division, a $175 million business, as Senior Vice President for over 2 years. Venkatraman spent 8 years at Jubilant Life Sciences as Senior Vice President of the API business. He led a $105 million division, establishing Jubilant as a global leader in specific molecules and expanding capacity to meet surging demand.

Read also: EMA validates submission of Marketing Authorization Application for skin cancer treatment Nidlegy: Sun Pharma, Philogen

Venkatraman's career also includes senior leadership roles at Wockhardt, Ranbaxy, and Kopran, where he consistently delivered on organizational objectives.

Venkatraman holds a Bachelor's degree in Chemical Engineering and a Master's degree in Management Studies from Mumbai University. 

Read also: Shilpa Medicare successfully completes Phase 1 clinical trial for Recombinant Human Albumin 20%

Wanbury Limited has a presence in API global market and domestic branded Formulation. Wanbury strength lies in Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India Formulation presence. The Company has a basket of over 13 API products. It has the larger customer base in Europe & US for Tramadol & Setraline (API).The Company has two US-FDA approved multi-product API facilities and one plant under operation for semi-regulated markets. It has pan-India presence in ethical formulations with a portfolio of close to 70 brands.

Read also: Sun Pharmaceutical Industry gets CDSCO Panel nod to study Fexuprazan HCL tablet for erosive esophagitis

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News